Uterine Corpus Leiomyoma
NCI Definition: A benign smooth muscle neoplasm arising from the body of the uterus. It is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern. 
Uterine corpus leiomyomas most frequently harbor alterations in USP28, TSC2, TSC1, TP53, and RUNX1 .
USP28 R732H, TSC2 R691L, TSC2 Mutation, TSC1 Mutation, and TSC1 M351V are the most common alterations in uterine corpus leiomyoma .
There is 1 clinical trial for uterine corpus leiomyoma, of which 1 is open and 0 are completed or closed. Of the trial that contains uterine corpus leiomyoma as an inclusion criterion, 1 is phase 2 (1 open).
Placebo and simvastatin are the most common interventions in uterine corpus leiomyoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.